JP5973467B2 - シルデナフィル遊離塩基含有フィルム製剤及びその製造方法 - Google Patents
シルデナフィル遊離塩基含有フィルム製剤及びその製造方法 Download PDFInfo
- Publication number
- JP5973467B2 JP5973467B2 JP2013553372A JP2013553372A JP5973467B2 JP 5973467 B2 JP5973467 B2 JP 5973467B2 JP 2013553372 A JP2013553372 A JP 2013553372A JP 2013553372 A JP2013553372 A JP 2013553372A JP 5973467 B2 JP5973467 B2 JP 5973467B2
- Authority
- JP
- Japan
- Prior art keywords
- free base
- film
- polymer
- sildenafil free
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 title claims description 126
- 229960003310 sildenafil Drugs 0.000 title claims description 63
- 239000012458 free base Substances 0.000 title claims description 61
- 238000004519 manufacturing process Methods 0.000 title claims description 59
- 238000002360 preparation method Methods 0.000 title description 6
- 239000002245 particle Substances 0.000 claims description 38
- 229920000642 polymer Polymers 0.000 claims description 37
- 239000000243 solution Substances 0.000 claims description 21
- 238000009826 distribution Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000002270 dispersing agent Substances 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 239000004014 plasticizer Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 239000004373 Pullulan Substances 0.000 claims description 7
- 229920001218 Pullulan Polymers 0.000 claims description 7
- 235000019423 pullulan Nutrition 0.000 claims description 7
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 5
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 5
- 239000000770 propane-1,2-diol alginate Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 description 21
- 238000000265 homogenisation Methods 0.000 description 13
- 239000002552 dosage form Substances 0.000 description 11
- 238000000576 coating method Methods 0.000 description 8
- 230000000704 physical effect Effects 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 7
- 239000000654 additive Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- -1 polyoxyethylene Polymers 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229960002639 sildenafil citrate Drugs 0.000 description 3
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229920003113 low viscosity grade hydroxypropyl cellulose Polymers 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Manufacture Of Macromolecular Shaped Articles (AREA)
- Moulding By Coating Moulds (AREA)
Description
予備実験として、ホモジナイザー(AGI Homomixer)のrpm(3,000または5,000)及び均質化(homogenization)時間(0分、10分または30分)によるシルデナフィル遊離塩基の粒度及びフィルム製造液状態における性状を確認した。フィルム製造液としては下記表6の実施例と同じ組成を使用した。
上記の実験より実験規模を大きくしながら、均質化時間によるシルデナフィル遊離塩基の粒径の変化を測定した。ホモジナイザーとしてIKA社の製品を使用し、5,000rpmで均質化時間を増加させながら実験を行った。均質化に使用されたシルデナフィル遊離塩基が含まれたフィルム製造液は、下記表6の実施例と同じ組成であった。測定結果を下記表3に示した。
より小さいシルデナフィル遊離塩基粒子を含むフィルムを製造するため、10,000rpmで1時間均質化してフィルムを製造した。ホモジナイザーとしてIKA社の製品を使用し、均質化に使用されたシルデナフィル遊離塩基が含まれたフィルム製造液は、下記表6の実施例8と同じ組成であった。測定結果を下記表4に示した。
上記のようにして得られたフィルム製造液の層分離有無及び製造されたフィルムの性状を観察した。また、フィルム製造液の上部と下部からそれぞれサンプルを採取してフィルムを製造し、単位重量を測定した。その結果を下記表5に示した。
製造方法及び組成毎の実施例を下記表6に示した。
1:味または異物感において非常に良くない
2:味または異物感において良くない
3:味または異物感において普通
4:味または異物感において非常に良い
Claims (10)
- 活性成分としてシルデナフィル遊離塩基を溶媒に懸濁させた高分子溶液を乾燥して製造するシルデナフィル遊離塩基含有フィルムの製造方法であって、
前記溶媒は、該溶媒の90重量%以上が水であり、
前記シルデナフィル遊離塩基が、粒度分布において10%に該当する粒径(D10)が8μm以上であり、90%に該当する粒径(D90)が100μm以下であることを特徴とするシルデナフィル遊離塩基含有フィルムの製造方法。 - 前記シルデナフィル遊離塩基が、粒度分布においてD10が5μm以上であり、D90が80μm以下であることを特徴とする請求項1に記載の製造方法。
- 前記高分子溶液が、シルデナフィル遊離塩基が溶解しないように溶媒の95重量%以上が水であることを特徴とする請求項1に記載の製造方法。
- 高分子及び可塑剤が溶解しており、溶媒の90重量%以上が水である溶液に、粒度分布においてD10が8μm以上であり、D90が100μm以下のシルデナフィル遊離塩基を懸濁させ、該溶液を乾燥して製造し、
乾燥したフィルム総重量対比高分子の含量は20ないし45重量%であり、可塑剤の含量は4ないし20重量%であり、シルデナフィル遊離塩基の含量は40ないし60重量%であることを特徴とするシルデナフィル遊離塩基含有フィルムの製造方法。 - 前記高分子が、2重量%の水溶液で測定してその粘度が15cp以下の高分子を含むことを特徴とする請求項1または請求項4に記載の製造方法。
- 前記高分子が、2重量%の水溶液で測定してその粘度が15cp以下の高分子と50cp以上の高分子との混合物であることを特徴とする請求項5に記載の製造方法。
- 前記高分子が、プルラン、アルギン酸プロピレングリコール、及びキサンタンガムの混合物であることを特徴とする請求項6に記載の製造方法。
- 前記溶液が、界面活性剤;分散化剤;または界面活性剤と分散化剤との混合物をさらに含むことを特徴とする請求項1または請求項4に記載の製造方法。
- 前記高分子が、プルランを含むことを特徴とする請求項1または請求項4に記載の製造方法。
- 使用される溶媒の量が、乾燥後に残留するフィルム構成物質の1重量部対比1.3ないし3.3重量部であることを特徴とする請求項1または請求項4に記載の製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0012516 | 2011-02-11 | ||
KR20110012516 | 2011-02-11 | ||
PCT/KR2012/001049 WO2012108738A2 (ko) | 2011-02-11 | 2012-02-13 | 실데나필 유리염기 함유 필름 제제 및 이의 제조 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014505098A JP2014505098A (ja) | 2014-02-27 |
JP5973467B2 true JP5973467B2 (ja) | 2016-08-23 |
Family
ID=46639094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013553372A Active JP5973467B2 (ja) | 2011-02-11 | 2012-02-13 | シルデナフィル遊離塩基含有フィルム製剤及びその製造方法 |
Country Status (19)
Country | Link |
---|---|
US (1) | US9907759B2 (ja) |
EP (1) | EP2674154B1 (ja) |
JP (1) | JP5973467B2 (ja) |
KR (1) | KR102010577B1 (ja) |
CN (2) | CN103402504B (ja) |
AU (1) | AU2012214939B2 (ja) |
BR (1) | BR112013020237A2 (ja) |
CA (1) | CA2827069C (ja) |
EA (2) | EA201500604A1 (ja) |
ES (1) | ES2691629T3 (ja) |
IL (1) | IL227931A (ja) |
MA (1) | MA34960B1 (ja) |
MX (1) | MX349803B (ja) |
MY (1) | MY163288A (ja) |
SG (1) | SG192284A1 (ja) |
TN (1) | TN2013000342A1 (ja) |
UA (1) | UA112540C2 (ja) |
WO (1) | WO2012108738A2 (ja) |
ZA (1) | ZA201306650B (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2864322C (en) * | 2012-02-28 | 2016-08-09 | Seoul Pharma. Co., Ltd. | High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient |
WO2014137189A1 (ko) * | 2013-03-07 | 2014-09-12 | 에스케이케미칼주식회사 | 고함량의 약물을 함유하는 구강 붕해 필름 및 이의 제조방법 |
CN105209025B (zh) * | 2013-04-11 | 2019-06-18 | 西梯茜生命工学股份有限公司 | 包括聚乙二醇类聚合物和/或乙烯基吡咯烷酮类聚合物作为分散稳定剂的含他达拉非游离碱的膜剂形式 |
US11116769B2 (en) | 2013-04-11 | 2021-09-14 | Ctc Bio, Inc. | Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer |
TWI671085B (zh) * | 2013-05-10 | 2019-09-11 | 韓商西梯茜生命工學股份有限公司 | 含有多奈哌齊游離鹽基之膜配方及其之製造方法 |
CN104352462A (zh) * | 2014-10-22 | 2015-02-18 | 张艳芬 | 一种提高昔多芬药物功效的方法 |
ES2584248B1 (es) * | 2015-03-24 | 2017-04-19 | Farmalider, S.A. | Composición farmacéutica de citrato de sildenafilo en forma de suspensión para uso oral |
CA3059527A1 (en) | 2017-04-14 | 2018-10-18 | Capsugel Belgium Nv | Pullulan capsules |
BR112019021396A2 (pt) | 2017-04-14 | 2020-04-28 | Capsugel Belgium Nv | processo para fabricação de pululano |
CN109010324B (zh) * | 2018-08-30 | 2021-07-02 | 南京康川济医药科技有限公司 | 一种西地那非口溶膜剂及其制备方法 |
US11179331B1 (en) | 2020-04-21 | 2021-11-23 | Cure Pharmaceutcai Holding Corp | Oral soluble film containing sildenafil citrate |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1239349A (en) * | 1983-10-10 | 1988-07-19 | Eberhard F. Gottwald | Pharmaceutical composition containing cimetidine |
GT199900061A (es) * | 1998-05-15 | 2000-10-14 | Pfizer | Formulaciones farmaceuticas. |
US6552024B1 (en) * | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
JP4173670B2 (ja) * | 2002-03-08 | 2008-10-29 | 旭化成ファーマ株式会社 | 口腔内崩壊製剤 |
JP5148801B2 (ja) | 2002-09-09 | 2013-02-20 | エスエス製薬株式会社 | 催眠用固形製剤 |
FR2850275B1 (fr) * | 2003-01-24 | 2005-04-08 | Scherer Technologies Inc R P | Capsules molles a macher contenant une substance active a gout masque |
US20050042177A1 (en) | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
JP4547994B2 (ja) * | 2004-06-02 | 2010-09-22 | 救急薬品工業株式会社 | 塊状物質含有積層フィルム状の可食性口腔内投与剤の製造方法および塊状物質含有積層フィルム状の可食性口腔内投与剤 |
AU2006212021B2 (en) * | 2005-02-10 | 2010-09-30 | Orexo Ab | Pharmaceutical compositions useful in the transmucosal administration of drugs |
EP2037752A2 (en) * | 2006-06-16 | 2009-03-25 | Tate & Lyle Ingredients Americas, Inc. | Pullulan films and their use in edible packaging |
PL2248519T3 (pl) * | 2006-10-02 | 2018-04-30 | Apr Applied Pharma Research S.A. | Niemukoadhezyjne postaci dawkowania w postaci filmu |
US20090047330A1 (en) * | 2007-08-17 | 2009-02-19 | Ramesh Bangalore | Oral fast dissolving films for erectile dysfunction bioactive agents |
KR100920106B1 (ko) * | 2007-11-14 | 2009-10-01 | 경북대학교 산학협력단 | 구연산 실데나필을 경피적으로 전달하기 위한 조절 약물전달체 및 이를 포함하는 경피 패치 |
KR101074271B1 (ko) * | 2009-06-25 | 2011-10-17 | (주)차바이오앤디오스텍 | 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름 |
KR20110041412A (ko) * | 2009-10-15 | 2011-04-21 | (주)씨엘팜 | Pde5 억제제를 함유하는 구강 용해성 필름 |
-
2012
- 2012-02-13 CN CN201280008427.5A patent/CN103402504B/zh active Active
- 2012-02-13 AU AU2012214939A patent/AU2012214939B2/en not_active Ceased
- 2012-02-13 CN CN201510567618.0A patent/CN105250242B/zh active Active
- 2012-02-13 KR KR1020120014086A patent/KR102010577B1/ko active IP Right Grant
- 2012-02-13 MA MA36227A patent/MA34960B1/fr unknown
- 2012-02-13 SG SG2013060595A patent/SG192284A1/en unknown
- 2012-02-13 UA UAA201310897A patent/UA112540C2/uk unknown
- 2012-02-13 BR BR112013020237-8A patent/BR112013020237A2/pt not_active IP Right Cessation
- 2012-02-13 MX MX2013009240A patent/MX349803B/es active IP Right Grant
- 2012-02-13 US US13/984,756 patent/US9907759B2/en active Active
- 2012-02-13 WO PCT/KR2012/001049 patent/WO2012108738A2/ko active Application Filing
- 2012-02-13 JP JP2013553372A patent/JP5973467B2/ja active Active
- 2012-02-13 EA EA201500604A patent/EA201500604A1/ru unknown
- 2012-02-13 ES ES12744173.1T patent/ES2691629T3/es active Active
- 2012-02-13 MY MYPI2013002963A patent/MY163288A/en unknown
- 2012-02-13 EA EA201391156A patent/EA027720B1/ru not_active IP Right Cessation
- 2012-02-13 EP EP12744173.1A patent/EP2674154B1/en active Active
- 2012-02-13 CA CA2827069A patent/CA2827069C/en active Active
-
2013
- 2013-08-07 TN TNP2013000342A patent/TN2013000342A1/fr unknown
- 2013-08-11 IL IL227931A patent/IL227931A/en active IP Right Grant
- 2013-09-04 ZA ZA2013/06650A patent/ZA201306650B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2827069A1 (en) | 2012-08-16 |
ZA201306650B (en) | 2015-06-24 |
EP2674154A4 (en) | 2015-04-01 |
MX2013009240A (es) | 2013-08-29 |
MY163288A (en) | 2017-08-30 |
EA027720B1 (ru) | 2017-08-31 |
MX349803B (es) | 2017-08-14 |
SG192284A1 (en) | 2013-09-30 |
CN103402504B (zh) | 2015-10-14 |
CN103402504A (zh) | 2013-11-20 |
CN105250242B (zh) | 2018-09-21 |
EP2674154A2 (en) | 2013-12-18 |
EP2674154B1 (en) | 2018-08-01 |
CA2827069C (en) | 2021-02-16 |
CN105250242A (zh) | 2016-01-20 |
US9907759B2 (en) | 2018-03-06 |
WO2012108738A2 (ko) | 2012-08-16 |
JP2014505098A (ja) | 2014-02-27 |
EA201391156A1 (ru) | 2014-02-28 |
KR102010577B1 (ko) | 2019-08-13 |
AU2012214939B2 (en) | 2016-11-17 |
US20130323307A1 (en) | 2013-12-05 |
AU2012214939A1 (en) | 2013-09-19 |
IL227931A (en) | 2017-03-30 |
KR20120101301A (ko) | 2012-09-13 |
ES2691629T3 (es) | 2018-11-28 |
BR112013020237A2 (pt) | 2021-03-16 |
IL227931A0 (en) | 2013-09-30 |
MA34960B1 (fr) | 2014-03-01 |
EA201500604A1 (ru) | 2015-09-30 |
TN2013000342A1 (en) | 2015-01-20 |
WO2012108738A3 (ko) | 2012-10-26 |
UA112540C2 (uk) | 2016-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5973467B2 (ja) | シルデナフィル遊離塩基含有フィルム製剤及びその製造方法 | |
JP6470257B2 (ja) | 分散安定化剤としてポリエチレングリコール系高分子及び/またはビニルピロリドン系高分子を含むタダラフィル遊離塩基含有フィルム剤形 | |
AU2013357113B2 (en) | Oral and/or buccal composition in the form of a thin film of a weakly soluble active ingredient, method of preparing same and use of same | |
CN114886874A (zh) | 口腔速溶膜剂及其制备方法 | |
TWI671085B (zh) | 含有多奈哌齊游離鹽基之膜配方及其之製造方法 | |
JP2012522742A (ja) | 7−[4−[4−(2,3−ジクロロフェニル)ピペラジン−1−イル]ブトキシ]−3,4−ジヒドロ−1h−キノリン−2−オン塩基またはその塩もしくは水和物を含む経口フィルム | |
US11116769B2 (en) | Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer | |
WO2012064087A2 (ko) | 아나스트로졸 함유 고분자 미립구를 유효성분으로 포함하는 약학적 조성물 | |
JP5919173B2 (ja) | 徐放性塩酸アンブロキソール口腔内崩壊錠 | |
TWI732762B (zh) | 口服持續釋放調配物 | |
OA16526A (en) | Sildenafil-free base-containing film preparation and method for producing same. | |
CN107823191A (zh) | 一种帕利哌酮口服速溶膜制剂及其制备工艺 | |
KR20150138671A (ko) | 타달라필을 함유하는 구강 붕해 필름 및 이의 제조방법 | |
JP2024526422A (ja) | 薬物組成物及びブレクスピプラゾール口腔内溶解フィルム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150204 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160115 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160415 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160621 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160714 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5973467 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |